ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 9, 2015

9:00AM-11:00AM
Abstract Number: 1163
Dynamic Regulation of Enhancers and Super-Enhancers in Rheumatoid Arthritis Synovial Finroblasts
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1563
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Rheumatoid Arthritis - Clinical Aspects Poster II
9:00AM-11:00AM
Abstract Number: 1638
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1948
Early Rheumatoid Arthritis Patients Have Higher Fractions of Circulating Th2 Cells, Th17 Cells and Regulatory T Cells, Similar Fractions of Follicular Helper T Cells, and Lower Fractions of Th17/Th1 Cells and Th1 Cells Compared to Healthy Controls
T cell Biology and Targets in Autoimmune Disease Poster I
9:00AM-11:00AM
Abstract Number: 1896
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II
9:00AM-11:00AM
Abstract Number: 1178
Educational Impact of a Clinical Anatomy Workshop on 1st-Year Orthopedic and Rheumatology Fellows and a Comparison of Scores Between Specialties in Mexico
Education Poster I
9:00AM-11:00AM
Abstract Number: 1311
Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial
Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT
9:00AM-11:00AM
Abstract Number: 1576
Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis - Clinical Aspects Poster II
9:00AM-11:00AM
Abstract Number: 1553
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Rheumatoid Arthritis - Clinical Aspects Poster II
9:00AM-11:00AM
Abstract Number: 1640
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1144
Effect of PEP-1-Glrx-1 on Catabolic Gene Expression in Human Articular Chondrocytes and in Mouse Carrageenan-Induced Paw Edema Model
Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis
9:00AM-11:00AM
Abstract Number: 1537
Effect of TNF-Alpha Blockade on Body Composition in Inflammatory Rheumatic Disease: Systematic Review with Meta-Analysis
Rheumatoid Arthritis - Clinical Aspects Poster II
9:00AM-11:00AM
Abstract Number: 1180
Effective Knowledge Transfer: A Demonstration of Video Illustration in the Immunology Curriculum for Rheumatology Trainees
Education Poster I
9:00AM-11:00AM
Abstract Number: 1655
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II
9:00AM-11:00AM
Abstract Number: 1491
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Quality Measures and Quality of Care Poster Session (ARHP): Clinical Practice/Patient Care
  • «Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 72
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology